
Physis Capital closes ₹400 Cr maiden fund, 60% deployed. LP base includes Haldiram's family office. Fund II planned for Q4 2026 as startup funding falls 26% in Q1.
Growth-stage venture capital firm Physis Capital has closed its maiden fund at ₹400 Cr ($48 Mn), with over 60% of the capital already deployed or committed across 10 startups. The remaining capital is earmarked for full deployment within the next six to eight months, targeting a concentrated portfolio of 15–20 companies by December 2026. The announcement lands during a period when Indian startup funding has declined by 8% year-over-year in 2025 and by 26% in the first quarter of 2026, according to Inc42's Annual Indian Startup Trends Report.
Physis Capital raised the fund from a mix of domestic institutional investors, corporate leaders, and prominent family offices. The limited partners include Star Union Dai-ichi Life Insurance, family offices of Haldiram's, Lotus Herbals, Ajmera Realty, Narayana Nethralaya, and the DS Group. The firm announced a first close at over ₹200 Cr last year, then roughly doubled the corpus to the final ₹400 Cr – indicating LP commitments increased as the portfolio took shape.
A 60% deployment rate before the final close suggests the firm placed early, high-conviction bets rather than waiting for market timing. In a down cycle, funds that deploy capital quickly and selectively often outperform those that wait for a recovery. Physis Capital's average cheque size ranges from $1–3 Mn, targeting Pre-Series A to Series B startups. A portion of the corpus is reserved for follow-on investments in what the firm calls its "highest-conviction" bets.
The fund's LP base includes insurance companies and family offices from consumer goods and real estate. These investors typically operate with a 10-year horizon and are less sensitive to quarterly mark-to-market volatility than fund-of-funds or institutional investors that require short-term liquidity. That alignment gives Physis Capital room to hold positions through follow-on rounds without pressure to exit early.
Current holdings reflect a focus on sectors where structural demand exists independent of funding cycles:
Each operates in areas tied to logistics efficiency, content localisation, or chronic disease management. Physis Capital managing partner Vinay Bansal described the firm's approach:
"We're focused on backing founders solving real, structural problems across India, whether it's access to capital, healthcare affordability, or building for the next wave of consumers beyond the metros. We look for teams building with conviction and depth."
The $1–3 Mn cheque range is narrower than many early-stage funds. That discipline forces a portfolio size of roughly 15–20 companies by final deployment. The reserved follow-on capital gives Physis the ability to double down on winners without fundraising again mid-cycle. In a market where later-stage rounds have become harder to close, that buffer matters.
| Year/Period | Total Startup Funding (India) |
|---|---|
| 2024 | $12 Bn |
| 2025 | $11 Bn |
| Q1 2026 | $2.3 Bn |
Funding volumes have become more muted compared to peak years of 2021 and 2022 as investors become more selective. The shift is supported by a maturing entrepreneurial ecosystem rather than cyclical capital flows alone.
Physis Capital plans to launch a "significantly larger" Fund II in the fourth quarter of 2026. The success of that raise will depend on the performance of the current portfolio. Two signals would confirm the thesis:
A signal that would weaken the case: a prolonged deployment delay or a portfolio company meltdown that forces a full reserve write-off.
Concentration cuts both ways. If one or two portfolio companies fail to reach Series B traction, the fund's overall return profile takes a hit. The 60% deployment rate also means only 40% of capital remains for new bets and follow-ons. Physis must balance fresh investments against supporting existing holdings.
The muted fundraising environment has made VC allocations more transparent. Funds that deploy quickly and selectively in down cycles often outperform those that wait for a recovery. For context on other Indian fund closes, see our coverage of a ₹500 Cr deeptech SME fund.
The sectors Physis Capital targets – consumer tech, fintech, and deeptech – are the same verticals that public market investors track for later-stage IPO candidates. The Q4 2026 Fund II launch will test whether the initial cohort can produce enough exits or strong follow-on marks to attract fresh capital.
This article does not constitute investment advice. Capital deployed in early-stage VC funds carries high risk and illiquidity. For broader market context, see our stock market analysis.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.